Bufexamac
drug drugOn this page
Also known as BufexamacoCP 1044 J3DuradermalNSC-758153ParfenacSID11112517SID26746938SID855633SID56422414SID124882428SID124882430SID144204073SID170465813
Summary
Bufexamac (CHEMBL94394) is an approved small-molecule non-narcotic analgesic (ATC M01AB17) targeting HDAC10 and HDAC6; indicated across 3 conditions including rheumatic disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: M01AB17 (+1 more)
- Targets: 2 (HDAC10, HDAC6)
- Indications: 3 conditions
- Chemistry: 223.27 Da · C12H17NO3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL94394 |
| Name | Bufexamac |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 2466 |
| ChEBI | CHEBI:31317 |
| ATC | M01AB17, M02AA09 |
| Molecular formula | C12H17NO3 |
| Molecular weight | 223.27 |
| InChIKey | MXJWRABVEGLYDG-UHFFFAOYSA-N |
SMILES: CCCCOC1=CC=C(C=C1)CC(=O)NO
IUPAC name: 2-(4-butoxyphenyl)-N-hydroxyacetamide
ChEBI definition: A hydroxamic acid derived from phenylacetamide in which the benzene moiety is substituted at C-4 by a butoxy group. It has anti-inflammatory, analgesic, and antipyretic properties.
Pharmacological roles (ChEBI): non-narcotic analgesic, non-steroidal anti-inflammatory drug, antipyretic.
Also known as: Bufexamac, Bufexamaco, CP 1044 J3, Duradermal, NSC-758153, Parfenac, SID11112517, SID26746938, SID855633, SID56422414, SID124882428, SID124882430
Patent coverage: 1,839 distinct patent families (6,619 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| HDAC10 | histone deacetylase 10 | Inhibition | 4.91 | 0% | Q969S8 |
| HDAC6 | histone deacetylase 6 | Inhibition | 4.97 | 0% | Q9UBN7 |
Broader ChEMBL bioactivity targets: 11 (assay-derived). Sample: Lysine-specific demethylase 4E, Survival motor neuron protein, Ferritin light chain, Protein deacetylase HDAC6, 3’,5’-cyclic-AMP phosphodiesterase 4A, Cytochrome P450 2D6, Polyunsaturated fatty acid 5-lipoxygenase, Cytochrome P450 1A2, Aminopeptidase N, Hypoxia-inducible factor 1-alpha, Polyamine deacetylase HDAC10.
Bioactivity
ChEMBL activities: 9 potent at pChembl ≥ 5 of 18 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| P12527 | 6.89 | IC50 | 128.8 | nM | CHEMBL_ACT_188770 |
| PDE4A | 6.28 | AC50 | 529.8 | nM | CHEMBL_ACT_25207625 |
| SMN1 | 5.85 | Potency | 1412 | nM | CHEMBL_ACT_3866348 |
| CYP1A2 | 5.8 | AC50 | 1585 | nM | CHEMBL_ACT_6068107 |
| HIF1A | 5.1 | Potency | 7943 | nM | CHEMBL_ACT_4131824 |
| HIF1A | 5.1 | Potency | 7943 | nM | CHEMBL_ACT_4519347 |
| P02791 | 5.05 | Potency | 8912 | nM | CHEMBL_ACT_4478788 |
| CYP2D6 | 5 | Potency | 10000 | nM | CHEMBL_ACT_4978061 |
| CYP2D6 | 5 | AC50 | 10000 | nM | CHEMBL_ACT_5987693 |
Target pathways
Aggregated over 2 target gene(s): HDAC10, HDAC6.
Top Reactome pathways
14 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| NOTCH1 Intracellular Domain Regulates Transcription | 2 | HDAC10, HDAC6 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | 2 | HDAC10, HDAC6 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 2 | HDAC10, HDAC6 |
| Notch-HLH transcription pathway | 2 | HDAC10, HDAC6 |
| Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells) | 2 | HDAC10, HDAC6 |
| HDACs deacetylate histones | 1 | HDAC10 |
| HSF1 activation | 1 | HDAC6 |
| Cilium Assembly | 1 | HDAC6 |
| Cargo trafficking to the periciliary membrane | 1 | HDAC6 |
| Transcriptional regulation by RUNX2 | 1 | HDAC6 |
| RUNX2 regulates osteoblast differentiation | 1 | HDAC6 |
| Chaperone Mediated Autophagy | 1 | HDAC6 |
| Late endosomal microautophagy | 1 | HDAC6 |
| Aggrephagy | 1 | HDAC6 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| chromatin organization | 2 |
| macroautophagy | 2 |
| negative regulation of DNA-templated transcription | 2 |
| autophagy | 2 |
| macromolecule deacylation | 2 |
| negative regulation of transcription by RNA polymerase II | 1 |
| DNA repair | 1 |
| regulation of DNA-templated transcription | 1 |
| positive regulation of mismatch repair | 1 |
| homologous recombination | 1 |
| obsolete polyamine deacetylation | 1 |
| obsolete spermidine deacetylation | 1 |
| DNA recombination | 1 |
| DNA damage response | 1 |
| protein polyubiquitination | 1 |
Indications & clinical
Indications
1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).
| Indication | Phase | MONDO | EFO |
|---|---|---|---|
| rheumatic disorder | 4 | MONDO:0005554 | EFO:0005755 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
89 molecules share ≥1 primary target. Top 89 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| BELINOSTAT | ChEMBL | Phase 4 (approved) | HDAC10, HDAC6 |
| BENDAMUSTINE | ChEMBL | Phase 4 (approved) | HDAC10, HDAC6 |
| CELECOXIB | ChEMBL | Phase 4 (approved) | HDAC10, HDAC6 |
| GIVINOSTAT | ChEMBL | Phase 4 (approved) | HDAC10, HDAC6 |
| PANOBINOSTAT | ChEMBL | Phase 4 (approved) | HDAC10, HDAC6 |
| PHENYLBUTANOIC ACID | ChEMBL | Phase 4 (approved) | HDAC10, HDAC6 |
| ROMIDEPSIN | ChEMBL | Phase 4 (approved) | HDAC10, HDAC6 |
| SODIUM PHENYLBUTYRATE | ChEMBL | Phase 4 (approved) | HDAC10, HDAC6 |
| VORINOSTAT | ChEMBL | Phase 4 (approved) | HDAC10, HDAC6 |
| ABEXINOSTAT | ChEMBL | Phase 3 | HDAC10, HDAC6 |
| CAFFEIC ACID | ChEMBL | Phase 3 | HDAC10, HDAC6 |
| CURCUMIN | ChEMBL | Phase 3 | HDAC10, HDAC6 |
| ENTINOSTAT | ChEMBL | Phase 3 | HDAC10, HDAC6 |
| PRACINOSTAT | ChEMBL | Phase 3 | HDAC10, HDAC6 |
| TACEDINALINE | ChEMBL | Phase 3 | HDAC10, HDAC6 |
| TUCIDINOSTAT | ChEMBL | Phase 3 | HDAC10, HDAC6 |
| AR-42 | ChEMBL | Phase 2 | HDAC10, HDAC6 |
| CHLOROGENIC ACID | ChEMBL | Phase 2 | HDAC10, HDAC6 |
| DACINOSTAT | ChEMBL | Phase 2 | HDAC10, HDAC6 |
| FIMEPINOSTAT | ChEMBL | Phase 2 | HDAC10, HDAC6 |
| NANATINOSTAT | ChEMBL | Phase 2 | HDAC10, HDAC6 |
| QUISINOSTAT | ChEMBL | Phase 2 | HDAC10, HDAC6 |
| RICOLINOSTAT | ChEMBL | Phase 2 | HDAC10, HDAC6 |
| Pazopanib | PubChem | Approved | HDAC10, HDAC6 |
| ABAMETAPIR | ChEMBL | Phase 4 (approved) | HDAC6 |
| ATALUREN | ChEMBL | Phase 4 (approved) | HDAC6 |
| ATORVASTATIN | ChEMBL | Phase 4 (approved) | HDAC6 |
| AXITINIB | ChEMBL | Phase 4 (approved) | HDAC6 |
| BORTEZOMIB | ChEMBL | Phase 4 (approved) | HDAC6 |
| DAUNORUBICIN | ChEMBL | Phase 4 (approved) | HDAC6 |
| EVANS BLUE FREE ACID | ChEMBL | Phase 4 (approved) | HDAC6 |
| FEBUXOSTAT | ChEMBL | Phase 4 (approved) | HDAC6 |
| FLUPHENAZINE | ChEMBL | Phase 4 (approved) | HDAC6 |
| GENTIAN VIOLET | ChEMBL | Phase 4 (approved) | HDAC6 |
| INDOPROFEN | ChEMBL | Phase 4 (approved) | HDAC6 |
| LOVASTATIN | ChEMBL | Phase 4 (approved) | HDAC6 |
| MARIBAVIR | ChEMBL | Phase 4 (approved) | HDAC6 |
| MONOBENZONE | ChEMBL | Phase 4 (approved) | HDAC6 |
| NITAZOXANIDE | ChEMBL | Phase 4 (approved) | HDAC6 |
| PHENYL AMINOSALICYLATE | ChEMBL | Phase 4 (approved) | HDAC6 |
| PIPERACETAZINE | ChEMBL | Phase 4 (approved) | HDAC6 |
| RUXOLITINIB | ChEMBL | Phase 4 (approved) | HDAC6 |
| THIABENDAZOLE | ChEMBL | Phase 4 (approved) | HDAC6 |
| TRIFLUPROMAZINE | ChEMBL | Phase 4 (approved) | HDAC6 |
| APABETALONE | ChEMBL | Phase 3 | HDAC6 |
| DACTOLISIB | ChEMBL | Phase 3 | HDAC6 |
| EBSELEN | ChEMBL | Phase 3 | HDAC6 |
| FLUPENTIXOL | ChEMBL | Phase 3 | HDAC6 |
| LINIFANIB | ChEMBL | Phase 3 | HDAC6 |
| OLVEREMBATINIB | ChEMBL | Phase 3 | HDAC6 |
| PIRARUBICIN | ChEMBL | Phase 3 | HDAC6 |
| QUERCETIN | ChEMBL | Phase 3 | HDAC6 |
| RESVERATROL | ChEMBL | Phase 3 | HDAC6 |
| VELIFLAPON | ChEMBL | Phase 3 | HDAC6 |
| ZUCLOPENTHIXOL | ChEMBL | Phase 3 | HDAC6 |
| AZD-6482 | ChEMBL | Phase 2 | HDAC6 |
| BAICALEIN | ChEMBL | Phase 2 | HDAC6 |
| BENZOXIQUINE | ChEMBL | Phase 2 | HDAC6 |
| CITARINOSTAT | ChEMBL | Phase 2 | HDAC6 |
| DAIDZEIN | ChEMBL | Phase 2 | HDAC6 |
| DOMATINOSTAT | ChEMBL | Phase 2 | HDAC10 |
| ENSULIZOLE | ChEMBL | Phase 2 | HDAC6 |
| EXALAMIDE | ChEMBL | Phase 2 | HDAC6 |
| EZUTROMID | ChEMBL | Phase 2 | HDAC6 |
| FENOBAM | ChEMBL | Phase 2 | HDAC6 |
| FGFR INHIBITOR DEBIO 1347 | ChEMBL | Phase 2 | HDAC6 |
| FISETIN | ChEMBL | Phase 2 | HDAC6 |
| FLUNIXIN | ChEMBL | Phase 2 | HDAC6 |
| FORMONONETIN | ChEMBL | Phase 2 | HDAC6 |
| FRENTIZOLE | ChEMBL | Phase 2 | HDAC6 |
| GENISTEIN | ChEMBL | Phase 2 | HDAC6 |
| IPRIFLAVONE | ChEMBL | Phase 2 | HDAC6 |
| IROSUSTAT | ChEMBL | Phase 2 | HDAC6 |
| LUTEOLIN | ChEMBL | Phase 2 | HDAC6 |
| MOCETINOSTAT | ChEMBL | Phase 2 | HDAC6 |
| NICOXAMAT | ChEMBL | Phase 2 | HDAC6 |
| PIPERINE | ChEMBL | Phase 2 | HDAC6 |
| PTEROSTILBENE | ChEMBL | Phase 2 | HDAC6 |
| RESMINOSTAT | ChEMBL | Phase 2 | HDAC6 |
| TIDEGLUSIB | ChEMBL | Phase 2 | HDAC6 |
| TINOSTAMUSTINE | ChEMBL | Phase 2 | HDAC6 |
| ZOLIMIDINE | ChEMBL | Phase 2 | HDAC6 |
| ZOTEPINE | ChEMBL | Phase 2 | HDAC6 |
| .gamma.-aminobutyric acid | PubChem | Approved | HDAC10 |
| acetylcysteine | PubChem | Approved | HDAC10 |
| Crizotinib | PubChem | Approved | HDAC6 |
| Gefitinib | PubChem | Approved | HDAC10 |
| Idelalisib | PubChem | Approved | HDAC6 |
| Tadalafil | PubChem | Approved | HDAC6 |
Related Atlas pages
- Genes: HDAC10, HDAC6
- Indicated for: rheumatic disorder
- Drugs: Belinostat, Bendamustine, Celecoxib, Givinostat, Panobinostat, Phenylbutanoic Acid, Romidepsin, Abexinostat, Caffeic Acid, Curcumin, Entinostat, Pracinostat, Tacedinaline, Tucidinostat, Pazopanib, Abametapir, Ataluren, Atorvastatin, Axitinib, Bortezomib, Daunorubicin, Evans Blue Free Acid, Febuxostat, Fluphenazine, Indoprofen, Lovastatin, Maribavir, Monobenzone, Nitazoxanide, Phenyl Aminosalicylate, Piperacetazine, Ruxolitinib, Thiabendazole, Triflupromazine, Apabetalone, Dactolisib, Ebselen, Flupentixol, Linifanib, Olverembatinib, Pirarubicin, Quercetin, Resveratrol, Veliflapon, Zuclopenthixol, acetylcysteine, Crizotinib, Gefitinib, Idelalisib, Tadalafil